CD38-directed monoclonal antibody

This page covers all CD38-directed monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD38.

Targets

CD38

Phase 3 pipeline (1)

• Daratumumab SC · Janssen Research & Development, LLC · Oncology
  Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.